VEEV
Fiscal year ends January Quarters are offset from the calendar — Q1 is Feb–Apr

Veeva Systems Inc. provides industry cloud solutions for the global life sciences industry, serving pharmaceutical, biotechnology, and medical devices companies. The company offers cloud software, data, and business consulting across four main product categories: Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud, and Veeva Data Cloud. Its solutions support research and development, quality, and commercialization functions, including clinical trial execution, regulatory information management, quality management, sales force automation, and marketing analytics. Veeva serves customers ranging from large pharmaceutical companies to emerging biotechs and clinical research sites. The company utilizes its proprietary Veeva Vault platform to build content and data-centric applications, and has introduced Veeva AI to integrate agentic artificial intelligence into its applications. Notable products include Veeva CRM, Veeva PromoMats, Veeva Medical, Veeva RIM, and Veeva Safety. Veeva also provides data solutions such as Veeva OpenData and Veeva Link applications for reference data and key opinion leader insights. The company operates as a Delaware public benefit corporation.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Software - Application Homepage veeva.com
Sector Technology IR page ir.veeva.com/overview/default.aspx
Tags
life sciences software, clinical trial management, regulatory information management, quality management, sales force automation, marketing analytics, medical affairs, pharmaceutical technology, biotechnology software, cloud computing, Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud, Veeva Data Cloud, Veeva Vault, Veeva Clinical Platform, Veeva Clinical Data Management, Veeva EDC, Veeva CDB, Veeva eTMF, Veeva CTMS, Veeva Safety, Veeva RIM, Veeva QMS, Veeva Quality Docs, Veeva Vault CRM Suite, Veeva CRM, Veeva Medical, Veeva PromoMats, Veeva Crossix, Veeva OpenData, Veeva Link, Veeva AI, Veeva Validation Management, Veeva Product Surveillance, Veeva Station Manager, Veeva Link Key People, Veeva Link Medical Insights, Commercial Evidence, Falcon Clinical, Falcon Regulatory, Veeva eSource, Veeva Submissions Publishing, Veeva Submissions Archive
Press page —

Metrics

Valuation  
Market cap $ 48.422B
Market cap (USD) $ 48.422B
P/E 48.97
PEG 2.12
P/BV 6.52
P/S 14.00
P/OCF 29.07
P/FCF 34.22
Dividend yield —
Turnover / mcap —
Returns  
ROE 13.9%
ROI 15.5%
ROIC 11.9%
Profit margin 28.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 23.1%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 86
Quality score 38.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 3.195B 2.747B 2.364B 2.155B 1.851B 1.465B 1.104B 862.21M 685.571M 544.043M 409.221M 313.222M 210.151M 129.548M
Net profit 908.906M 714.138M 525.705M 487.706M 427.39M 379.998M 301.118M 229.832M 141.966M 68.804M 54.46M 40.383M 23.615M 18.783M
Free cash flow 1.415B 1.09B 911.339M 780.47M 764.463M — 434.262M 302.387M 223.804M 137.088M 59.001M 41.043M 39.893M 29.835M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 231.43 210.25 203.47 175.14 255.48 290.21 147.74 113.95 62 42.2 24.14 28.46 32.1 —
Price performance 12m 0.1 0.03 0.16 -0.31 -0.12 0.96 0.3 0.84 0.47 0.75 -0.15 -0.11 — —

Filed figures

Figure Jan 2017 Jan 2018 Jan 2019 Jan 2020 Jan 2021 Jan 2022 Jan 2023 Jan 2024 Jan 2025 Jan 2026
Balance sheet detail
Trade receivables (USD) 183M 234M 303M 390M 564M 631M 703M 852M 1.02B 1.26B
↳ YoY growth +26.3% +27.9% +29.8% +28.4% +44.8% +11.8% +11.4% +21.2% +19.3% +23.9%
↳ 5y CAGR +44.5% +39.0% +33.3% +31.3% +28.1% +24.6% +22.9% +21.1% +17.4%
Lease liabilities (USD) — — — 54.8M 62.7M 54.6M 61M 55.8M 75.8M 95.9M
Cash and deposits (USD) 218M 320M 551M 477M 731M 1.14B 886M 703M 1.12B 1.42B
Intangible assets (USD) 39.3M 31.5M 24.5M 135M 115M 102M 82.5M 63M 44.5M 30.3M
Right-of-use assets (USD) — — — 49.1M 56.9M 49.6M 55.3M 45.6M 63.9M 75.6M
Cash flow detail
Operating cash flow (USD) 144M 233M 311M 437M 551M 764M 780M 911M 1.09B 1.42B
Purchases of property, plant and equipment (USD) -6.92M -9.63M -8.44M -3.11M — — — — — —
Purchases of intangible assets (USD) -584,000 -1.73M -1.38M -1.21M -8.68M -14.2M -13.5M -26.2M -20.5M -29.1M
Change in receivables (cash effect) (USD) -38.1M -50.7M -79M -55.5M -174M -67M -72.2M -150M -165M -245M
Change in payables (cash effect) (USD) 1.11M 1.4M 1.82M 2.81M 754,000 -3M 21.4M -10.2M -1.96M 6.08M
Share buybacks (cash effect) (USD) — — — — — — — 0.00 0.00 -170M
Income taxes paid (cash effect) (USD) -14.2M -12.5M -19.5M -14.3M -18.1M -58.6M -168M -134M -322M -230M
Share-based compensation (USD) 40.8M 54M 76.4M 116M 185M 235M 352M 394M 437M 473M
Operating cash flow before change in receivables (USD) 182M 284M 390M 493M 725M 831M 853M 1.06B 1.25B 1.66B
Free cash flow (OCF - PPE - intangibles) (USD) 137M 222M 301M 433M — — — — — —
Income detail
Research and development expense (USD) 96.8M 132M 159M 210M 294M 382M 520M 629M 693M 767M
↳ 5y CAGR +65.7% +55.3% +43.2% +38.5% +34.9% +31.6% +31.6% +31.7% +27.0% +21.1%
Total comprehensive income (USD) 68.7M 143M 229M 301M 381M 414M 469M 546M 716M 925M
Comprehensive income to owners (USD) 68.7M 143M 229M 301M 381M 414M 469M 546M 716M 925M
Provision for credit losses (USD) 130,000 -242,000 198,000 244,000 -307,000 272,000 256,000 693,000 — —
Credit cost ratio (credit losses / average receivables) (%) 0.1% 0.1% 0.1% 0.1% 0.1% 0.0% 0.0% 0.1% — —
Reported Mar 30, 2017 Mar 30, 2018 Mar 28, 2019 Mar 30, 2020 Mar 30, 2021 Mar 30, 2022 Mar 30, 2023 Mar 20, 2026 Mar 20, 2026 Mar 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

As previously announced, on November 5, 2026, Veeva Systems Inc. (the “Company”) presented its 2026 Investor Day, which was accessible via live webcast through (and a replay of the presentation is currently available on) the Company’s investor relations website.

On August 26, 2026, in its quarterly earnings conference call, the Company had previously provided preliminary guidance for certain of the Company’s anticipated financial metrics for the third quarter of fiscal year 2027. During the Investor Day presentation, Brian Van Wagener, the Company’s Chief Financial Officer, presented a slide containing the previously announced guidance and stated that the Company expects to report third quarter of fiscal year 2027 results that meet or exceed the previously announced guidance. A copy of the slide is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

UCB Selects Veeva Vault CRM Bull 2 Bear 0 Order/contract

November 4, 2026

Agentic CRM platform to drive unified engagement worldwide

PLEASANTON, Calif., Nov. 4, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that UCB has committed to Veeva Vault CRM, the agentic engagement platform for life sciences. Vault CRM provides industry-specific AI to accelerate launch and drive better customer experiences.

Veeva Systems

"We are excited to strengthen our strategic partnership with Veeva by moving to Vault CRM," said Edwin Erckens, chief digital technology officer at UCB. "We share a deep commitment to customer success, and Vault CRM will provide UCB the technology foundation to drive commercial execution."

"Vault CRM is the customer engagement platform that will provide UCB with a stable, scalable, and future-ready technology foundation that will advance UCB's commercial strategy," said Chris Moore, president of Veeva Europe. "Working together with UCB, we will support them in that critical mission."

Vault CRM is part of Vault CRM Suite, the technology foundation for agentic commercial. The Agentic Call Report in Vault CRM creates Commercial Evidence to uncover previously hidden treatment barriers.

About Veeva SystemsVeeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended July 31, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

| Contact: | |

| Maria Scurry Veeva Systems [email protected] | Meera Lakhani-Patel Veeva Systems, Europe [email protected] |

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ucb-selects-veeva-vault-crm-302928843.html

SOURCE Veeva Systems

View All News

Company Logo

Opt-Out Request Honored

Cookie Settings

When you visit our website, we store strictly necessary cookies on your browser. You cannot opt out of our use of strictly necessary cookies because these cookies are deployed in order to ensure the proper functioning of our website (such as allowing you to log into your account, redirecting you when you log out and remembering your input when you fill out a form.) Click below for more information about our use of strictly necessary cookies. For information about our privacy practices, please review our Privacy Notice below. Privacy Notice

Allow All

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but if you do, some parts of the site will not work. These cookies do not store any personally identifiable information.

Cookies Details

Functional Cookies

Functional Cookies

Always Inactive

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies, then these services may not function properly.

Cookies Details

Targeting Cookies

Targeting Cookies

Always Inactive

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant advertisements on other sites. They do not store directly personal information but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookies Details

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Powered by Onetrust

Skip to content

Company Logo

Opt-Out Request Honored

Cookie Settings

When you visit our website, we store strictly necessary cookies on your browser. You cannot opt out of our use of strictly necessary cookies because these cookies are deployed in order to ensure the proper functioning of our website (such as allowing you to log into your account, redirecting you when you log out and remembering your input when you fill out a form.) Click below for more information about our use of strictly necessary cookies. For information about our privacy practices, please review our Privacy Notice below. Privacy Notice

Allow All

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but if you do, some parts of the site will not work. These cookies do not store any personally identifiable information.

Cookies Details

Functional Cookies

Functional Cookies

Always Inactive

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies, then these services may not function properly.

Cookies Details

Targeting Cookies

Targeting Cookies

Always Inactive

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant advertisements on other sites. They do not store directly personal information but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookies Details

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Powered by Onetrust

Prompts

Veeva Systems Inc. (ticker VEEV), listed in United States.

ETFs Holding Veeva Systems Inc.

ETF Weight in ETF Shares Market value As of
LGHT 5.60% 780 $ 138.427K Jun 30, 2026
JGRW 3.49% 10,732 $ 3.066M Aug 31, 2026
XOVR 3.16% 389,906 $ 69.197M Jun 30, 2026
STRN 2.98% 2,507 $ 750.295K Nov 17, 2026
FORH 2.87% 3,188 $ 565.774K Jun 30, 2026
FCUS 2.58% 6,438 $ 1.927M Nov 17, 2026
LRGG 2.13% 31,736 $ 5.632M Jun 30, 2026
FMED 1.66% 3,000 $ 857.07K Aug 31, 2026
FDND 1.62% 504 $ 153.604K Nov 11, 2026
CVAR 1.55% 3,263 $ 664.934K Jul 31, 2026
LSEQ 1.30% 722 $ 217.705K Nov 13, 2026
JTEK 1.21% 165,699 $ 47.789M Nov 17, 2026
SURE 0.97% 1,925 $ 555.189K Nov 17, 2026
PINK 0.97% 11,212 $ 3.234M Nov 17, 2026
FLCV 0.95% 4,639 $ 1.325M Aug 31, 2026
CGMM 0.90% 108,731 $ 32.541M Nov 16, 2026
SROI 0.89% 820 $ 167.1K Jul 31, 2026
TMAT 0.88% 10,261 $ 2.091M Jul 31, 2026
BRES 0.85% 17,945 $ 5.18M Nov 18, 2026
FFF 0.82% 182 $ 51.952K Sep 30, 2026
BRNY 0.81% 15,600 $ 4.5M Nov 18, 2026
DSTL 0.80% 96,054 $ 17.047M Jun 30, 2026
MKTN 0.74% 4,430 $ 786.192K Jun 30, 2026
ESUM 0.71% 6,328 $ 1.29M Jul 31, 2026
FLCG 0.69% 14,878 $ 4.25M Aug 31, 2026
FLCC 0.66% 3,072 $ 877.64K Aug 31, 2026
BCHP 0.65% 8,005 $ 1.421M Jun 30, 2026
UPSD 0.60% 3,427 $ 698.354K Jul 31, 2026
ALAI 0.50% 12,819 $ 2.275M Jun 30, 2026
AVMC 0.47% 8,699 $ 2.603M Nov 16, 2026
MCDS 0.46% 125 $ 36.051K Nov 17, 2026
ACGR 0.45% 166 $ 47.425K Aug 31, 2026
JGRO 0.40% 124,221 $ 35.827M Nov 17, 2026
AOTG 0.39% 1,418 $ 405.108K Aug 31, 2026
SEIM 0.34% 28,840 $ 5.118M Jun 30, 2026
LCTU 0.29% 11,036 $ 3.303M Nov 16, 2026
AVUQ 0.19% 2,732 $ 817.633K Nov 16, 2026
MSLC 0.17% 24,322 $ 6.949M Aug 31, 2026
HEQQ 0.17% 172 $ 49.607K Nov 17, 2026
PEPS 0.15% 238 $ 42.238K Jun 30, 2026
CAPE 0.12% 1,659 $ 294.423K Jun 30, 2026
RILA 0.11% 235 $ 47.888K Jul 31, 2026
XMAG 0.11% 755 $ 228.327K Nov 13, 2026
ENHU 0.11% 34 $ 10.176K Nov 16, 2026
IALT 0.11% 30,282 $ 9.063M Nov 16, 2026
DFSU 0.10% 7,872 $ 2.381M Nov 12, 2026
PHEQ 0.10% 767 $ 136.119K Jun 30, 2026
AVLC 0.09% 4,992 $ 1.494M Nov 16, 2026
DFUV 0.08% 42,468 $ 12.843M Nov 12, 2026
DFUS 0.06% 45,726 $ 13.828M Nov 12, 2026
AVSU 0.06% 980 $ 293.294K Nov 16, 2026
AAUS 0.06% 975 $ 280K Nov 18, 2026
DFAU 0.06% 25,349 $ 7.666M Nov 12, 2026
DFAC 0.06% 167,490 $ 50.652M Nov 12, 2026
GDE 0.06% 951 $ 271.691K Aug 31, 2026
MODL 0.06% 3,244 $ 575.713K Jun 30, 2026
TACU 0.06% 34 $ 10.176K Nov 17, 2026
AVUS 0.05% 25,284 $ 7.567M Nov 16, 2026
NTSD 0.05% 95 $ 16.86K Jun 30, 2026
FMDE 0.04% 17,927 $ 3.182M Jun 30, 2026
NTSX 0.04% 3,052 $ 541.638K Jun 30, 2026
DCOR 0.04% 57,636 $ 17.43M Nov 12, 2026
HCMT 0.04% 1,044 $ 212.746K Jul 31, 2026
APUE 0.04% 3,082 $ 880.497K Aug 31, 2026
DFLV 0.03% 8,265 $ 2.5M Nov 12, 2026
VSLU 0.03% 996 $ 176.76K Jun 30, 2026
VOXP 0.03% 9 $ 1,834.02 Jul 31, 2026
DYNF 0.03% 48,231 $ 14.435M Nov 16, 2026
INRO 0.03% 678 $ 202.912K Nov 16, 2026
THRO 0.03% 11,402 $ 3.412M Nov 16, 2026
ACVF 0.03% 220 $ 44.832K Jul 31, 2026
NPFE 0.02% 649 $ 132.253K Jul 31, 2026
CSHP 0.02% 297 $ 88.886K Nov 16, 2026
GSPY 0.02% 520 $ 155.626K Nov 17, 2026
EBI 0.00% 16 $ 4,571.04 Aug 31, 2026
FELC 0.00% 6 $ 1,064.82 Jun 30, 2026
CORO 0.00% 94 $ 28.208K Nov 16, 2026
GVLU 0.00% 4 $ 1,197.12 Nov 17, 2026